Medical Device | April 01, 2024
MTD acquires Ypsomed's pen needle and BGM businesses
This acquisition enables MTD to open new, strategic markets
This acquisition enables MTD to open new, strategic markets
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company had earlier announced about the approval received from the MHRA for Liraglutide
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Subscribe To Our Newsletter & Stay Updated
